EMA clears Vertex' Symkevi + Kalydeco for cystic fibrosis in children aged 6-11, the first disease-modifying therapy patients in this age group with two F508del mutations or one F508del and a ...

Find the latest Pulmonology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.